Abstract Development of biological targeted therapies and immune checkpoint inhibitors has redefined the treatment for many cancers; however, the increasing use of new protocols has led to physicians observing a new spectrum of toxicities. To date, oral adverse events induced by these new anticancer therapies have been mainly reported using nonspecific terminology (Bstomatitis,^Bmucosal inflammation,^Bmucositis^) and remain poorly characterized, with the exception of mammalian target of rapamycin (mTOR) inhibitor-associated stomatitis. Oral toxicities of targeted therapies often display very characteristic features which clearly differ from classic oral injuries observed with cytotoxic chemotherapy and/or radiotherapy. In addition, they frequently affect more than 20% of treated patients and can lead to a significant morbidity or permanent treatment discontinuation. Oral mucosal toxicities described in this review include mTOR inhibitor-associated stomatitis (mIAS); stomatitis, benign migratory glossitis, and osteonecrosis of the jaw associated with multi-targeted kinase inhibitors of the VEGF and PDGF receptors; mucositis induced by EGFR inhibitors (in monotherapy or in combination with head and neck radiotherapy and/or chemotherapy); hyperkeratotic lesions with BRAF inhibitors; pigmentary changes and lichenoid reactions secondary to imatinib; and more recent data on the BOsler-Weber-Rendu-like syndrome^described with the antibody-drug conjugate, TDM-1. Finally, we provide, to our knowledge, the first available structured data on oral toxicities induced by the new recently FDA-and EMA-approved monoclonal antibodies targeting PD-1. Clinical management of these targeted therapy-related oral changes is also discussed.
Introduction
Substantial progress in our understanding of the mechanism of oncogenesis has led to the emergence of numerous targeted anticancer therapies in the last decade [1] [2] [3] [4] . Their therapeutic effects result mostly from the inhibition of specific molecular receptors and intracellular signaling pathways involved in tumor progression. Immune checkpoint inhibitors are also emerging as promising anticancer agents for a wide range of cancers (e.g., metastatic melanoma, advanced or refractory nonsmall cell lung cancer, renal cell cancer, Hodgkin lymphoma) by enhancing immune responses against malignant cells [5] [6] [7] [8] [9] . Their use is expected to increase exponentially in the future as their approval is extended to different tumor types [10, 11] . Both targeted agents and immunotherapies now represent a major part of the oncologists' therapeutic arsenal and have redefined the treatment principles for many cancers.
Cutaneous toxicities are among the most frequently observed adverse events associated with the majority of targeted therapies. These toxicities are now well characterized, both in terms of their prevalence and in their multiple clinical manifestations [12] [13] [14] [15] [16] [17] [18] . Cutaneous toxicities also represent the most prevalent immune-related adverse events (IRae) associated with anticancer immunotherapies. The mechanism of action of immune checkpoint inhibitors involves triggering cytotoxic T-cell activation and induces a specific toxicity profile that is primarily of immunologic origin [5, 19, 20] .
Oral changes induced by targeted therapies are less well described and have been only sporadically characterized mainly reported using nonspecific terminology (Bstomatitis,B mucositis^), except for mammalian target of rapamycin (mTOR) inhibitor-associated stomatitis (mIAS). However, oral toxicities of targeted therapies ( [6-9, 20, 34-37] , even though a spectrum of associated oral adverse events has recently emerged [20, 37, 38] .
The purpose of our review is to describe the main oral mucosal changes observed with targeted therapies and immune checkpoint inhibitors. These oral toxicities clearly differ from classic oral injuries observed with chemotherapy and/or radiation therapy but might similarly impair patients' quality of life and might require dose modification or discontinuation of the treatment. (Table 1) mTOR inhibitor-associated stomatitis (mIAS)
Mammalian target of rapamycin (mTOR) inhibitors
Incidence mIAS or aphthous-like stomatitis is a frequent and well-characterized oral toxicity in cancer patients treated with mTOR inhibitor therapy (everolimus, temsirolimus, deferolimus) [22, 27, 28, 32, 39] . The lesions are very similar to those initially described in transplant patients treated with sirolimus [32, 40] . mIAS is considered as a class effect [22] , for which meta-analyses indicate the overall incidence of any grade and high grade (≥3) (following NCI-CTCae) ranges from 33.5 to 52.9% and from 4.1 to 5.4%, respectively, regardless of the type of mTOR inhibitor therapy [22, 39] .
Overall, mIAS represents the most prevalent adverse event associated with this therapy and is the most frequent doselimiting toxicity [22, 39] . It is also the third most frequent severe adverse event associated with mTOR inhibitors (everolimus, temsirolimus) [12, 22, 27, 29, 39 ] that can lead to dose modifications [22, 32, 39, 41] in about 5% of treated patients [22] . In addition, mIAS accounts for more than 10% of reasons for treatment discontinuation, reported to affect 2% of treated patients [22, 42] .
Finally, it is important to note that the incidence of mIAS reported in pivotal studies has shown a tendency to decrease over time, potentially due to prevention and earlier management, as well as patient education.
Comparison between everolimus and temsirolimus Everolimus-induced mIAS represents the most common adverse event reported with this drug [43] [44] [45] [46] [47] [48] . The incidence of mIAS of any grade associated with everolimus ranges from 24 to 64%, according to the main pivotal studies [7, 43, [45] [46] [47] [48] (Table 2) . This incidence appears higher than that of all-grade mIAS induced by temsirolimus, which ranges from 14 to 40% of treated patients [49] [50] [51] [52] (Table 2) . Moreover, indirect comparisons between temsirolimus and everolimus reveal that the incidence of high-grade (≥3) mIAS with temsirolimus is less than 7% [49] [50] [51] [52] and slightly lower than with everolimus [7, 43, [45] [46] [47] [48] (Table 2) . mTOR inhibitors in combination with endocrine agents In patients treated for breast cancer with the combination of everolimus and exemestane, mIAS represents the most common severe adverse event leading to dose reduction or interruption [42] and is the second most frequent cause of treatment discontinuation [101, 102] . In the BOLERO-2 trial, the incidence of all-grade stomatitis was 67% (with 33% grade ≥2 and 8% with grade 3 toxicity) in patients treated with everolimus (10 mg per day) plus exemestane (25 mg per day) for metastatic breast cancer [102] . In summary, this therapeutic combination significantly increases the incidence of all-grade mIAS [44, 101, 102] compared to everolimus monotherapy.
Clinical presentation mIAS is now a well-described clinical toxicity which mostly occurs within the first cycle of treatment [22, 29, 41] , with a median time to onset of 10 days following the initiation of the treatment [27, 32, 39] . In the BOLERO-2 trial, the median time to grade ≥2 onset was 2 weeks [102] . In addition, a recent meta-analysis conducted on phase 3 trials of everolimus (alone or in combination) as a treatment for different forms of solid cancers and tuberous sclerosis complex showed that a second flare occurred in about 40% of treated patients [42] . Nonetheless, both the rate of occurrence and degree of severity of mIAS generally decrease during the subsequent cycles of treatment [22] . mIAS is characterized by single or multiple, painful, and well-circumscribed round/ovoid superficial ulcers. The lesions generally measure a few millimeters in diameter and (Fig. 1a, b) . Major lesions can nonetheless sometimes be observed (Fig. 1c) . mIAS mainly develops on the nonkeratinized mucosa (buccal mucosa, soft palate, ventral side and lateral borders of the tongue, or floor of the mouth) [22, 27, 32, 39] . These clinical features clearly differ from cytotoxic chemotherapy-induced mucositis, in which lesions are often more diffuse, larger, poorly circumscribed, and covered with a pseudomembrane consisting of fibrin, altered leucocytes, and epithelial debris (Fig. 2) [21, [103] [104] [105] . Gastrointestinal involvement is also frequently observed in mucositis associated with chemotherapy, whereas mIAS typically spares other mucosae [27, 28, 32, 39, 42] .
Management mIAS is a significant complication that can negatively impair adherence to the cancer treatment and affect the patient's quality of life. Therefore, prophylactic treatment and early recognition of this toxicity are fundamental.
Prevention
Early management consists of the promotion of good oral hygiene. Firstly, pretherapeutic oral screening is recommended in order to identify dental or periodontal disease outbreaks and ensure proper treatment. Oral examination is also necessary to eliminate potential sources of trauma (ill-fitting dentures, defective restorations, broken teeth, dental calculus, etc.) and detect preexisting mucosal disease [106] . Good oral health also relies on basic oral care interventions [33, [106] [107] [108] [109] [110] (Table 3) . In a recent phase 2 prevention trial (SWISH trial), Rugo et al. [111] reported on the prophylactic use of 10 mL of alcohol-free dexamethasone (0.5 mg/5 mL, four times daily for 8 weeks) mouthwash to prevent mIAS in patients receiving everolimus 10 mg/exemestane 25 mg for HR+, HER2− advanced or metastatic breast cancer. The incidence of all-grade mIAS in this group was 21.2%, with 2.4% developing grade ≥2 mIAS, and no patients developing grade 3. Indirect comparison with the BOLERO-2 trial clearly indicates that prophylaxis with dexamethasone mouthwash significantly reduces the incidence or prevents the occurrence of all grades of mIAS, especially grade ≥2 mIAS.
Treatment
In general, no intervention is required for grade 1 mIAS, except for maintaining a good standard of oral hygiene. Topical steroids should be considered as the first line of treatment for grade 2 mIAS [22, 32, 33, 39, 11 2 ] . Topical steroid mouthrinse (e.g., Price et al. [72] III N = 1010p Chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer; panitumumab Motzer et al. [83] III N = 570p Clear-cell metastatic RCC; dovitinib (500 mg orally according to a 5-days-on and 2-days-off schedule) or sorafenib (400 mg orally twice daily). 
Motzer et al. [84] III N = 723p Clear-cell metastatic RCC, axitinib (5 mg twice daily) or sorafenib (400 mg twice daily). Motzer et al. [83] III N = 570p Clear-cell metastatic RCC; dovitinib (500 mg orally according to a 5-days-on and 2-days-off schedule) or sorafenib (400 mg orally twice daily). Motzer et al. [86] III N = 1110p Metastatic RCC; continuous dose of pazopanib (800 mg once daily) or sunitinib in 6-week cycles (50 mg once daily for 4 weeks, followed by 2 weeks without treatment). Cheng et al. [85] III N = 1074p Advanced hepatocellular cancer; sunitinib 37.5 mg once/day or sorafenib 400 mg twice/day.
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Motzer et al. [86] III N = 1110p Metastatic RCC; continuous dose of pazopanib (800 mg once daily) or sunitinib in 6-week cycles (50 mg once daily for 4 weeks, followed by 2 weeks without treatment). Motzer et al. [87] I I N = 750p Metastatic RCC; either repeated 6-week cycles of sunitinib (at a dose of 50 mg given orally once daily for 4 weeks, followed by 2 weeks without treatment) or interferon alfa (at a dose of 9 MU
given subcutaneously three times weekly). Demetri et al. [93] III N = 147p Advanced GIST; 400 mg or 600 mg of imatinib/day. dexamethasone mouth rinse (0.1 mg/mL)) is the preferred treatment in case of multiple lesions or lesions that are difficult to reach for local application [33] . For limited lesions that can be reached for topical application, high potency corticosteroids (clobetasol 0.05% gel or cream) is an alternative. In cases where the lesion does not resolve, a combination of intralesional steroid injections (e.g., triamcinolone) and clobetasol 0.05% gel or cream should be used for treatment. The association of low-level laser therapy (wavelength of 633-685 or 780-830 nm, power output of between 10 and 150 mW, energy density 2-3 J/cm 2 , and no more than 6 J/cm 2 on the tissue surface treated) [113] with topical corticosteroids provides some immediate pain relief and may promote healing of the ulcerations. These data need to be confirmed by prospective studies. For highly painful (grade ≥3), intolerable grade 2 or recurrent mIAS, dose reduction or treatment interruption (see below) and systemic corticosteroids should be considered (high-dose pulse therapy with 30-60 mg or 1 mg/kg oral prednisone/prednisolone for 1 week, followed by dose tapering over the second week) [33] , while continuing topical interventions. Antifungal therapy may be administrated on a case by case basis [112] . For moderate pain management, anesthetic mouthwash (lidocaine viscous, 2%), topical analgesic (e.g., doxepin rinse), coating agents or systemic analgesics can be helpful. Topical nonsteroidal anti-inflammatory drugs (amlexanox 5% oral paste) or paracetamol, in combination with an immediate release oral opioid or fast acting fentanyl preparation, have been proposed as management options. In case of severe pain, other types of analgesic administration routes should be considered [33] . Dose reduction, interruption, or discontinuation (see Table 4 ) mIAS may also be managed by dose adjustments. The severity and/or the recurrence of the lesions as well as the time needed to recover will determine whether full dosing can be resumed or whether dose reduction or discontinuation is required [101, 102, 110, 114, 115] .
Dysgeusia
Incidence Everolimus also frequently causes dysgeusia, which has been reported in 9 to 32% of treated patients [43] [44] [45] 48] (Table 2) . However, no dose adjustment is generally necessary (Table 2) . Although less frequently described, dysgeusia can also be induced by temsirolimus [116] .
Management As dysgeusia is benign, it is frequently overlooked. Nevertheless, the impact on patients' quality of life can be significant, with a higher risk of malnutrition and weight loss [117] [118] [119] [120] [121] . To date, there is no standardized preventive or curative treatment for dysgeusia [122] and symptomatic dietary measures should be considered (Table 5 ). Weight monitoring is recommended. The management of contributing factors is also crucial (e.g., smoking, alcoholism, poor oral hygiene, oropharyngeal infections) [121] .
Other toxicities
Xerostomia has been reported in only one comparative study, in which it occurred in 6% of everolimus-treated patients [7] (Table 2) . It is generally mild in this context. No cases of temsirolimus-associated xerostomia have been reported. Basic oral care and dietary recommendations associated with artificial saliva substitutes (moisturizing spray, glycerol-based oral spray) should be recommended if the symptoms severely impact health-related quality of life (Table 5) .
Rare cases of osteonecrosis of the jaw have been very sporadically reported with everolimus [123] mostly when it has been used in association with antiresorptive agents [124] .
EGFR and pan-HER inhibitors (Table 1) Agents targeting the epidermal growth factor receptor (EGFR or HER1) also represent an important strategy in the management of many cancers (colorectal, lung, head and neck, and 
Oral examination by specialist practitioner:
• Before oncologic treatment: preoperative dental and periodontal screening with treatment as appropriate • Elimination of traumatic factors (dental or prosthetic origin)
• During and after treatment: regular dental and periodontal examination Fig. 2 Widespread mucositis of the lateral ventral side of the tongue induced by chemotherapy (nonkeratinized mucosa) breast cancers). They include monoclonal antibodies (cetuximab, panitumumab) and specific tyrosine kinase inhibitors (erlotinib, gefitinib). This group also includes also multitargeted kinase inhibitors, targeting both the EGF receptor and other receptors of the HER (or ErbB) family, such as afatinib, lapatinib, and dacomitinib. Given the fundamental role of EGFR in homeostasis of the epidermal and epithelial cells, the therapeutic inhibition of this receptor is associated with cutaneous or mucosal toxicities in the majority of anti-EGFR-treated patients [12, 14, 23, 125, 126] .
Mucositis
Incidence EGFR/HER1 tyrosine kinase inhibitors (Table 1) Oral adverse events induced by tyrosine kinase inhibitors targeting EGFR are less frequently reported than skin toxicities [125, 127] .
The incidence of mucositis induced by erlotinib in monotherapy varies between 8 and 20% [58, 65, 67, 68] (Table 2) . Similar, although slightly higher, incidence values of 17 to 24% have been reported for gefitinib [54, 63, 64, 128] (Table 2) . Moreover, the incidence rate of high-grade (≥3) mucositis has never been reported to exceed 1%, neither with erlotinib nor gefitinib. As a consequence, few treated patients require dose modifications as a result of oral mucositis [68, 128] .
Pan-HER tyrosine kinase inhibitors (Table 1) Conversely, with the new generation of pan-HER tyrosine kinase inhibitors, mucositis appears to be one of the main toxicities, after paronychia, diarrhea, and papulopustular rash [55, 59, 128, 129] . The incidence of all-grade mucositis induced by afatinib appears to be significantly higher than that of erlotinib-or gefitinib-induced mucositis [128] and ranges from 25 to 72.1% [54] [55] [56] [57] [58] [59] [60] (Table 2) .
Dacomitinib, another irreversible pan-HER tyrosine kinase inhibitor [69] , also induces mucositis more frequently Table 3 than erlotinib or gefitinib [65] and is associated with an allgrade incidence of about 40%, similar to that of afatinib [69, 70] (Table 2 ). In addition, high-grade (≥3) mucositis induced by afatinib and dacomitinib may occur in 3 to 8.7% of treated patients [54-59, 65, 69, 70] (Table 2) , which may lead to more frequent dose reductions or discontinuation of the treatment.
Monoclonal antibodies targeting EGFR (Table 1) Mucositis appears to occur less frequently with cetuximab or panitumumab monotherapy than with tyrosine kinase inhibitors [30] . These monoclonal antibodies, however, are seldom used as a monotherapy and are usually combined with chemotherapeutic regimens and/or radiation therapy. In one comparative phase III study, the incidence of all-grade mucositis was 7% in patients treated with cetuximab and 5% in those treated with panitumumab (<1% of grade 3 in both groups) [72] (Table 2) . High-grade (≥3) mucositis was also noted in less than 1% of patients in an earlier study of patients treated with cetuximab monotherapy [71] (Table 2) .
Cetuximab or panitumumab in combination with chemotherapy
Cetuximab and panitumumab are most often used in association with chemotherapy (fluorouracil, cisplatin, folfox, or folfiri chemotherapeutic regimens), particularly when being used for the treatment of advanced colorectal and head and neck cancers. Cetuximab and panitumumab when combined with chemotherapy both significantly increase the risk of developing mucositis of any grade compared to chemotherapy alone [77-79, 81, 82, 130, 131] (Table 2) , with a relative risk of high-grade (≥3) Extensive resection is solely indicated in cases of extended necrosis. a Basic oral care: see Table 3 b Dietary recommendations: frequent drinks between meals, maintaining good oral hygiene, chewing slowly, diversifying and favoring foods for which flavor is not too distorted, and further enhancing the flavor of food using seasonings and flavorings, consuming cold foods, and avoiding overly fragrant foods mucositis ranging from 2.69 [131] to 3.44 [130] .
Cetuximab in association with head and neck radiation therapy
The incidence of high-grade (≥3) mucositis is high when cetuximab is combined with radiotherapy (about 60%) [73, 75, 132] . The main pivotal studies [73, 75, 132] (Table 2) , however, indicate that the addition of cetuximab to radiotherapy does not have a significant impact on the incidence of high-grade (≥3) mucositis in comparison to radiotherapy alone [73] [74] [75] (Table 2 ). More recently, Bonner et al. reported that, regardless of p16 status, the addition of cetuximab to cervical radiotherapy did not impact the incidence, time to onset, severity, or duration of mucositis [132] (Table 2) .
However, our experience and that of other authors [133] indicates that a higher incidence of severe mucositis is commonly observed with this therapeutic combination. The same tendency is observed when combining cetuximab with head and neck radio-chemotherapy, versus head and neck radio-chemotherapy alone [76] ( Table 2) . Finally, the incidence of high-grade (≥3) mucositis also seems to be higher when cetuximab is used in combination with radiotherapy than when chemotherapy is used in combination with radiotherapy in head and neck cancer [74] (Table 2) .
Clinical presentation In most cases, HER inhibitor-induced mucositis in monotherapy corresponds to a moderate erythema with limited and superficial ulcers (Fig. 3a-c) , occurring shortly after treatment introduction [21, 125, 133] . This form of mucositis sometimes takes on the appearance of aphthouslike lesions, although these lesions are less typical than those described above with mTOR inhibitors. All areas of the nonkeratinized oral mucosa may be involved. Lip lesions are quite common, including erythema, erosions, cracks [129] , and angular cheilitis [134] . Deeper mucosal ulcerations are occasionally noted and more common when used in combination with cytotoxic therapies. Associated symptoms may range from mild tenderness to pain and difficulties with food intake [125, 134] .
Head and neck radiotherapy alone is associated with mucosal lesions strictly confined onto the irradiation fields. These lesions involve both keratinized (Fig. 3d) and nonkeratinized mucosa. The addition of cetuximab to cervical radiotherapy for locally advanced squamous cell carcinoma is also associated with severe lesions involving both nonkeratinized and keratinized areas. Paradoxically, anterior and labial mucosal involvement (Fig. 3e ) is more common, even though these locations generally receive a lower total dose of irradiation [135] . These lesions are frequently multiple and polycyclic and often associated with significant functional impairment. Interestingly, mucosal pain may present with limited mucosal change. Similarly, the association of monoclonal antibodies targeting EGFR with chemotherapy is associated with more severe mucosal involvement (Fig. 3f) .
Management As for mIAS, prevention of EGFR inhibitorassociated mucositis relies on maintaining good oral hygiene resulting from basic oral care interventions (Table 3 ) and prior elimination of outbreaks and sources of local trauma [106, 125] . Treatment guidelines were initially based on the MASCC guidelines for the management of cytotoxic chemotherapy-and radiotherapy-induced mucositis [107, 125] . The latest ESMO clinical practice guidelines [33] suggest, as for mIAS, using steroids (topical, intralesional or systemic) as the first-line treatment for mucositis induced by anti-EGFR therapy. Like mIAS, the use of low-level laser therapy [113] and 0.2% morphine mouthwash or doxepin rinse may improve control of symptoms and pain particularly patients with grade ≥3 mucositis, treated with cetuximab combined with chemotherapy and/or head and neck radiotherapy [33] .
Dose adjustment-offset of radiotherapy session
In general, no dose adjustment is needed for EGFR tyrosine kinase inhibitor-associated grade 1 or 2 mucositis. For patients with grade 3 mucositis, temporary discontinuation of treatment may be necessary. The EGFR tyrosine kinase inhibitor treatment can resume at half the initial dose once mucositis has improved to grade 2, and then be increased as long as there is no worsening of symptoms [129] . Cessation of cetuximab therapy is recommended for patients with grade ≥3 mucositis associated with the combined use of cetuximab and head and neck radiotherapy [136] . Generally, the radiation dose or schedule is not compromised by such events [136] .
Other oral toxicities
Dysgueusia and xerostomia are mainly reported with new generation HER tyrosine kinase inhibitors. Dysgeusia has been described in 6 to 15% of patients treated with dacomitinib and afatinib [55, 69, 70] (Table 2 ). In addition, 8 to 14% of patients treated with dacomitinib have been reported to develop xerostomia [69, 70] (Table 2) .
Angiogenesis inhibitors (Table 1)
This class of targeted therapies is characterized by its inhibitory effect on tumor neoangiogenesis. It includes monoclonal antibodies that directly inhibit vascular endothelial growth factor (VEGF) (bevacizumab, ramucirumab) and tyrosine kinase inhibitors that target angiogenic receptors (vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR)), and other signaling pathways (sunitinib, sorafenib, pazopanib, axitinib, cabozantinib).
The main oral toxicities reported in pivotal studies include nonspecific stomatitis, dysgeusia, and xerostomia, which may occur alone or in association. Approximately one quarter of patients treated with multitargeted antiangiogenic kinase inhibitors develop an oral adverse event within the first 2 months of starting therapy [25] . Sunitinib and sorafenib are the two drugs that are most frequently associated with oral adverse events [25] , but oral toxicities have also been frequently reported with cabozantinib, a new multitargeted kinase inhibitor.
Dose adjustment (<10% of treated patients) [25, 137] and treatment discontinuation (about 1% of treated patients) [25, 137] due to oral toxicities are rarely needed.
In contrast, bevacizumab and ramucirumab-induced stomatitis is uncommon.
Stomatitis
Incidence In the main pivotal studies [7, 45, 48, 51, [83] [84] [85] [86] [87] [88] [89] [90] 138] (Table 2) , the incidence of all-grade stomatitis induced by angiogenesis inhibitors ranges from 7 to 29%, depending on the drug used. Comparative studies underlines that the incidence of all-grade angiogenesis inhibitor-associated stomatitis is lower than that of all-grade mIAS [7, 28, 45, 48, 51] (Table 2) .
With sunitinib, stomatitis appears to be one of the most frequent adverse events after diarrhea, fatigue, and nausea [89, 139] . Main pivotal studies have reported that the incidence of any grade stomatitis ranges from 16.5 to 27% with sunitinib [45, [85] [86] [87] [88] [89] (Table 2 ). The incidence of any grade stomatitis associated with sunitinib appears to be higher than that of stomatitis associated with other multitargeted antiangiogenic kinase inhibitors, in particular sorafenib-for which the incidence of all-grade stomatitis is reported to range from 7 to 19% [51, [83] [84] [85] (Table 2) .
On the other hand, the incidence of all-grade stomatitis with cabozantinib is similar to that reported with sunitinib, having been reported in 22 to 29% of treated patients [48, 90] (Table 2) .
The incidence of high-grade (≥3) stomatitis has never been reported to exceed 4% with any multitargeted angiogenesis inhibitor [7, 45, 48, 83, 84, [86] [87] [88] [89] 139] (Table 2) .
Clinical presentation The broad term Bstomatitis^has been used to describe mucosal injuries or toxicities, such as mucosal sensitivity, taste alterations, dry mouth, and necrosis of jaw associated with angiogenesis inhibitors [26] . However, the stomatitis induced by this therapeutic family is more of a diffuse mucosal hypersensitivity/dysesthesia [25] , in some cases associated with moderate erythema [28] or painful inflammation of the oral mucosa (including burning mouth, discomfort induced by hot or spicy foods) [25] . Such symptoms appear quite rapidly in the first weeks of treatment [28, 140] and gradually disappear [21, 25] . In some cases, well-limited ulcerations of the nonkeratinized mucosa were also noted (Fig. 4) . Unusually, the stomatitis may manifest as linear lingual ulcers of the nonkeratinized mucosa, particularly with sunitinib or sorafenib [21, 137] .
Management Management of angiogenesis inhibitor-induced stomatitis currently relies on the same prophylactic and curative interventions as described for mIAS or stomatitis induced by EGFR inhibitors (Table 5 ). Mucosal sensitivity may require dietary modifications, such as avoiding irritating foods and tobacco [25] .
Dysgeusia
Dysgeusia appears to be the second most frequent oral adverse event [25] induced by multitargeted antiangiogenic kinase inhibitors. Taste changes are most often reported with sunitinib and cabozantinib, for which the incidence of all-grade dysgeusia ranges from 20 to 49% [45, [86] [87] [88] [89] and 24 to 34% of treated patients [48, 90] , respectively ( Table 2) . High-grade dysgeusia is clearly uncommon, occurring in below 1% of treated patients [7, 45, 48, 83, 84, [86] [87] [88] [89] 138] (Table 2) .
Comparative studies indicate that dysgeusia is more common in patients treated with angiogenesis inhibitors than in those treated with mTOR inhibitors [45, 48] (Table 2) .
Benign migratory glossitis
Patients treated with angiogenesis inhibitors may also develop benign migratory glossitis or geographic tongue. This adverse event was initially described with bevacizumab [141] , and we have reported the occurrence of similar lesions with sorafenib and sunitinib [142] . These lesions gradually regress after treatment discontinuation (Fig. 5a, b) . We have also observed geographic tongue with pazopanib ( Fig. 6 ) and axitinib. The impact of these events remains unclear [143] . Induced benign migratory glossitis can be moderately painful but usually does not require any treatment modification or specific local treatment [21] (Table 5 ).
Other oral toxicities
Xerostomia Depending on the series, 4 to 12% of patients treated with multitargeted antiangiogenic tyrosine kinase inhibitors develop grade 1 to 2 xerostomia [7, 45, 83, 87] (Table 2) .
Bleeding and delayed healing The inhibition of VEGF or its receptors by angiogenesis inhibitors (sorafenib, sunitinib, vandetanib, axitinib, bevacizumab, etc.) induces significant changes in vascular permeability and can promote mucocutaneous bleeding [144] . Between 20 and 40% of patients treated with bevacizumab reported moderate bleeding, mostly of the nasal mucosa [12, 138] . Delayed wound healing can also occur with antiangiogenic agents (sunitinib, bevacizumab); these adverse events should be considered before oral surgery.
Medication related osteonecrosis of the jaw (MRONJ) In oncology, MRONJ is known to occur with antiresorptive agents (bisphosphonates-zoledronic acid, pamidronate, and inhibitor of receptor activator of nuclear factor κB ligand (RANKL), denosumab) and occurs in 3 to 10% of treated patients depending on the indication (osseous metastases or myeloma) [145] . The association of these drugs with antiangiogenic targeted therapies (sunitinib, bevacizumab) increases the risk to develop MRONJ (Fig. 7) [145, 146] more often after oral surgery [147] [148] [149] . Few data of MRONJ are also reported with sorafenib, cabozantinib, alfibercept, and mTOR inhibitor monotherapy [124, 147] . MRONJ remains an underdiagnosed adverse event because of inadequate or restrictive diagnostic criteria [147] and because early lesions may have few symptoms. Strategies for management rely on expert opinion [150] . Depending on the stage, antibacterial mouthwashes, pain medication, and antibiotics may be recommended. Conservative measures or surgical debridement can be successful during the early stages. Extensive resection of necrotic bone is indicated solely in cases of extended necrosis [148] (Table 5 ).
Recommendations for oral surgery
Before introduction of antiangiogenic treatment, patients should undergo oral screening (including a comprehensive oral exam with radiographs), be informed about maintaining oral hygiene and should receive all necessary dental treatments [151] . The dentist should contact the oncologist before any oral surgery is carried out on patients treated with angiogenesis inhibitors. Dental/ periodontal management should be limited to unavoidable surgical interventions during the course of antiangiogenic treatment. The therapeutic window should always be evaluated during antiangiogenic targeted therapy. Monoclonal antibodies and tyrosine kinase inhibitors might be stopped at least 2 and 1 week, respectively, before oral surgery. The treatment can be reinitiated after mucosal healing. Dental screening and preoperative dental treatments remain key management approaches for prevention of MRONJ and delayed healing [149] [150] [151] .
Mucosal yellow discoloration Although quite exceptional, yellow diffuse staining of the oral mucosa (Fig. 8 ) can be observed with sunitinib. This induced coloration occurs frequently in the skin and appears to be directly related to the color of the drug itself. It is associated with characteristic colored urine [152] . No specific management is required.
Hyperkeratotic lesions Finally, we have observed sporadic cases of oral hyperkeratotic lesions in patients treated with the pan-RAF inhibitor, sorafenib. In addition, this multitargeted antiangiogenic tyrosine kinase inhibitor has recently been reported to induce development of oral squamous cell carcinoma [144] .
BCR-ABL inhibitor: imatinib (Table 1) Imatinib is a first-generation BCR-ABL inhibitor targeting c-KIT and the PDGFR. It is frequently associated with oral toxicities which are now well-characterized.
Lichenoid reactions
Development of oral lichenoid reactions [153] [154] [155] (Fig. 9) is the most frequent oral adverse event of imatinib. It can occur in isolation or in association with lichenoid nail or skin lesions [155] [156] [157] [158] . This toxicity has only rarely been reported in the literature [155] . Our clinical experience indicates that these mucosal lesions are relatively frequent but probably underestimated due to their typically asymptomatic nature. The lesions are polymorphic, combining more or less characteristic reticular/striated lesions with symptomatic ulcerative, Fig. 8 Yellow pigmentation of the soft palate with sunitinib Fig. 9 Lichenoid lesion of the border of the tongue induced by imatinib Fig. 7 Osteonecrosis of the jaw induced by the association of bevacizumab and denosumab erosive, or atrophic lesions. They are preferentially localized on the buccal or lingual mucosa [153, [157] [158] [159] .
These lesions gradually develop after a few months of treatment [154, 155, 159] . Their discovery is often fortuitous, and thus, systematic oral examination of the oral cavity is required in patients treated with imatinib.
Given the potential risk of malignant transformation of lichenoid reactions, regular monitoring of these lesions is recommended [160] ; however, it is not known if the lichenoid changes seen with imatinib may have malignant risk. Symptomatic forms are generally treated with high potency topical corticosteroid therapy, and imatinib treatment can be continued in almost all cases.
To our knowledge, there have been no reports of similar lesions with new generation BCR-ABL inhibitors, such as dasatinib, nilotinib, ponatinib, or bosutinib.
Pigmentary changes
More unusually, a fairly typical Bblue-gray^asymptomatic hyperpigmentation of the hard palate may be noted in patients treated with imatinib ( Fig. 10 ) [161] [162] [163] [164] [165] [166] . Pigmentation in other locations has been described in anecdotal reports [167] . Discovery of the oral hyperpigmentation is usually fortuitous, and the time of onset is unknown. The pathophysiological mechanism seems similar to that of hyperpigmentation due to antimalarials (drug metabolite deposition in the mucosa and complex formation with hemosiderin or melanin) [18] . Direct inhibition of c-kit (which is physiologically expressed in the oral mucosa) by imatinib has been also implicated in this mechanism by some authors [161, 162] .
To your knowledge, this reaction has not been described with new generation BCR-ABL inhibitors.
Immune checkpoint inhibitors (Table 1) Use of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death-1 (PD1) and its ligand (PDL-1) inhibitors, either as single agents or in combination, results in a distinct spectrum of toxicities, mostly related to activation of the immune system [168] . Among the multiple IRae reported with these drugs, dermatologic toxicities represent the most frequent adverse events [19, 20, 168] .
Use of both PD-L1 and PD-1 (nivolumab, pembrolizumab) inhibitors has been found to be associated with nonspecific stomatitis or oral mucosal inflammation in sporadic cases [35, 36, 47, 169, 170] , but no grade ≥3 adverse events have been reported. Recently, more characteristic oral lesions with PD-1 or PD-L1 inhibitors have been described [20, 38, 171, 172] .
Xerostomia
Xerostomia (generally grade 1-2) has been reported in about 6% of patients treated with nivolumab [6, 34] (Table 2) for melanoma ( Fig. 11a) and in between about 4 and 7.2% of pembrolizumab-treated patients [8] (Table 2 ). In addition, we have observed severe grade 3 xerostomia in exceptional cases (Fig. 11b) . The xerostomia shows clinical features of a Gougerot-Sjögren-like syndrome, with cytotoxic T-lymphocyte infiltration of accessory salivary glands (Fig. 11c) . However, anti SSA and anti SSB antibodies screening is generally negative.
Dysgeusia
Moderate dysgeusia (grade 1 or 2) has been noted in less than 3% of PD-1 and PD-L-1-treated patients [8, 9, 35, 47] (Table 2 ). Xerostomia and dysgeusia appear less commonly with the anti-CTLA-4 agent, ipilimumab [8] ( Table 2 ).
Lichenoid reactions
Schaberg et al. [172] reported one case of lichenoid lesion with PDL-1 inhibitor therapy and Hofmann et al. [171] reported one case of oral lichen planus with pembrolizumab. We have also observed several cases of mucosal lesions, which were clinically and histologically consistent with oral lichenoid lesions, developing as a result of treatment with PD-1 and PD-L-1 [20] . These lesions generally occurred several months after treatment induction. Histopathology and immunophenotypic analysis of the lichenoid lesions associated with anti-PD1 and anti-PDL-1 therapy seem to reveal greater histiocytic infiltrate than that observed in similar nondrug-related lichenoid reactions (i.e., lichen planus, lichen planus-like keratoses) [172] .
Lesions may appear as whitish papules (confluent in places), in reticular or linear streaks, and are sometimes associated with erythema. The dorsal and lateral sides of the tongue, lips, gingiva, hard palate, or buccal mucosae (Fig. 12a-c) can be involved. Patients may report pain or soreness but the lesions can also be asymptomatic. The perianal area or vulva can also be affected [172] . Topical corticosteroids should be considered if lesions are painful (Table 5) .
BRAF inhibitors (Table 1) Vemurafenib and dabrafenib are two FDA-approved selective BRAF inhibitors for the treatment of mutated BRAF V600 metastatic melanoma. When used in monotherapy, dermatologic adverse events, particularly hyperkeratotic lesions, represent the most common toxicities of these targeted therapies. A broad spectrum of induced hyperkeratotic lesions has been reported, including verrucous papillomas, keratosis pilaris-like rashes, and malignant epithelial tumors, such as keratoacanthoma or squamous cell carcinoma [173] [174] [175] . Hyperkeratotic lesions are probably induced by proliferation of wild-type BRAF keratinocytes, secondary to the paradoxical activation of the intracellular mitogen-activated protein (MAP) kinase pathway [174, 176, 177] .
The oral toxicity of BRAF inhibitors has only been described recently [31, 178, 179] . This toxicity is characterized by the sometimes rapid development of asymptomatic hyperkeratotic multifocal mucosal lesions on both the keratinized and nonkeratinized mucosa, predominantly located on the linea alba (Fig. 13a) , the marginal gingiva, the hard palate (Fig. 13b) , the lateral borders of the tongue (Fig. 13c) , or the labial mucosa. All lesions exhibit similar features and sometimes have a verrucous or papillomatous appearance [31] . We have recently reported the first case of squamous cell carcinoma (SCC) on vemurafenib-induced hyperkeratotic lesions of the labial mucosa [31] . Due to the usually asymptomatic nature of these lesions and the lack of systematic oral examinations in treated patients, the incidence of induced hyperkeratotic lesions is not known.
As the incidence of BRAF inhibitor-induced cutaneous SCC is clearly higher than that of oral SCC, oral examinations should be carried out on a regular basis at all follow up visits and oral hyperkeratotic lesions should be treated with caution and biopsy is recommended in case of doubt. Furthermore, anecdotal observations of vemurafenib-induced inflammatory gingival hyperplasia have been recently reported [178, 179] .
BRAF inhibitors are now mostly used in combination with MEK inhibitors (vemurafenib with cobimetinib, and dabrafenib with trametinib). By blocking the downstream MAP kinase pathway, MEK inhibitors significantly restrict the development of secondary hyperkeratotic lesions [13, 180] . Therefore, it is anticipated that these mucosal lesions will be less reported in the near future.
Other targeted therapies with oral toxicities ALK inhibitors (Table 1) Crizotinib is an oral small-molecule tyrosine kinase inhibitor targeting the anaplastic lymphoma kinase (ALK), MET, and ROS1 tyrosine kinases. The main reported oral toxicity induced by this therapy is moderate dysgeusia (grade 1 or 2) (Table 2), which affects 11 to 26% of treated patients [95] [96] [97] [98] (Table 2) . Moreover, all-grade stomatitis occurs in less than 15% of treated patients, with no reports of any high-grade ≥3 cases [98] (Table 2) .
Hedgehog pathway inhibitors (Table 1) Vismodegib is a first-in-class, oral, selective Hedgehog pathway inhibitor, FDA-approved for the treatment of locallyadvanced or metastatic basal cell carcinomas. One of the most frequent reported toxicities is grade 1/2 dysgeusia, for which the incidence ranges from 51 to 84% depending on the series [13, 99, 100, 181] (Table 2) . High-grade ≥3 dysgeusia has been reported in about 2% of treated patients (Basset-Seguin et al. 100). Furthermore, vismodegib also induces ageusia [100] ( Table 2) in 22% of treated patients, with an incidence of 2% for high-grade ≥3 toxicity. Dysgeusia is the second most common vismodegib-induced adverse event after muscle spasms [100, 181] . It can lead to treatment interruption (6% of patients) and generally occurs within the first 6 months of therapy [181] .
Management (Table 5 ) Due to the high incidence of vismodegib-induced taste changes, informing and educating patients about this adverse event is required at initiation of vismodegib therapy. Early nutritional screening and routine nutritional counseling from a dietician should be considered in order to prevent significant weight loss. Investigation of the nature and severity of taste changes require study in order that approaches to management can be developed [182] .
Trastuzumab-emtansine (T-DM-1) ( Table 1) We have recently described the development of cutaneous (Fig. 14a ) and mucosal telangiectasias (Fig. 14b, c) , mimicking Osler-Weber-Rendu syndrome [183, 184] , with the antibody-drug conjugate ado-trastuzumab emtansine (T-DM-1, FDA-approved for the treatment of HER2+ metastatic breast cancer).
These oral mucosal lesions can be observed on the whole mucosa (palate, tongue, lips, and jugal mucosa). They blanch during diascopy and appear dome-shaped with surrounding small radiating dilated vessels. On the skin, they appear as spider telangiectasias.
Epistaxis, digestive, or gynecological bleeding occurs in about 30% of T-DM-1-treated patients, without the systematic presence of associated thrombocytopenia. These bleeding events may, at least in part, be linked to the mucosal vascular malformations [184] . Given the potential risk of hemorrhage, screening for mucosal telangiectasia is recommended (Table 5) .
Conclusion
Oral toxicities of targeted therapies and immune checkpoint inhibitors develop less frequently than the more common and prominent cutaneous toxicities. However, the oral changes may be underreported using general toxicity scales and relying upon patient report. These oral adverse events also appear to be less symptomatic than chemotherapy-induced mucositis but may require dose adjustments. Oral lesions can be clinically quite specific, and systematic examination of the oral mucosa is recommended as part of the monitoring regimen of patients treated with these drugs. Physicians should be aware of these induced mucosal changes. Early recognition and appropriate management are necessary in order to limit dose modifications and preserve patients' quality of life. Study of approach to management of oral toxicities is required to improve guidance for improved patient care. 
